tiprankstipranks
Trending News
More News >
60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ:SXTP
US Market
Advertisement

60 Degrees Pharmaceuticals, Inc. (SXTP) AI Stock Analysis

Compare
180 Followers

Top Page

SX

60 Degrees Pharmaceuticals, Inc.

(NASDAQ:SXTP)

Rating:43Neutral
Price Target:
$1.50
▲(7.91%Upside)
The overall score is influenced primarily by significant financial difficulties and bearish technical indicators, indicating fundamental and market challenges. The recent capital raise is a positive development, providing some support for future operations.
Positive Factors
Market Opportunity
The company survey indicates that Babesiosis prevalence could be significantly higher than CDC estimates, suggesting a larger potential market for Tafenoquine.
Product Revenue
Product revenues showed a significant year-over-year increase, despite being supply-constrained.
Sales Growth
Arakoda sales continue to grow, with net product revenues reaching $607,574 in FY24, a significant increase from $253,573 in FY23.
Negative Factors
Earnings
Q1 earnings per share were below estimates due to higher than forecast SG&A expenses.
Expense Management
Higher than expected SG&A expenses impacted the company's financial performance, leading to earnings per share falling below estimates.

60 Degrees Pharmaceuticals, Inc. (SXTP) vs. SPDR S&P 500 ETF (SPY)

60 Degrees Pharmaceuticals, Inc. Business Overview & Revenue Model

Company Description60 Degrees Pharmaceuticals, Inc. (SXTP) is a pharmaceutical company specializing in the development and commercialization of treatments for tropical diseases. The company's core focus is on providing innovative solutions for the prevention and treatment of diseases such as malaria and dengue fever. By leveraging scientific research and strategic collaborations, 60 Degrees Pharmaceuticals seeks to enhance global health outcomes particularly in areas most affected by these conditions.
How the Company Makes Money60 Degrees Pharmaceuticals, Inc. generates revenue through the development and sale of pharmaceutical products designed to treat and prevent tropical diseases. The company earns income from product sales, licensing agreements, and research and development collaborations. Key revenue streams include government contracts, partnerships with non-governmental organizations, and sales to international markets where tropical diseases are prevalent. Additionally, the company may receive funding and grants from global health initiatives and foundations that support the fight against infectious diseases.

60 Degrees Pharmaceuticals, Inc. Financial Statement Overview

Summary
The company is facing significant financial challenges with declining revenues, persistent losses, and negative cash flow. Though there have been some improvements in equity and debt reduction, profitability and cash generation remain critical concerns.
Income Statement
35
Negative
The company has been experiencing declining revenues, with a significant drop in total revenue from 2020 to 2023. Gross profit margin has been negative in recent years, indicating cost management issues. Net profit margin has been consistently negative, reflecting ongoing unprofitability. Despite some revenue growth in 2024, profitability remains a major concern.
Balance Sheet
40
Negative
The debt-to-equity ratio improved significantly from previous years due to reduced total liabilities, but the company still has challenges with negative equity in past years. In 2024, equity became positive, which is a positive sign. The equity ratio indicates a relatively higher reliance on equity compared to previous years.
Cash Flow
30
Negative
The company has struggled with negative operating cash flow in recent years, indicating challenges with cash generation from core operations. Free cash flow has also been negative, reflecting ongoing investment and financing needs. Positive financing cash flows suggest reliance on external funding.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue607.57K253.57K223.21K1.16M2.18M
Gross Profit222.81K-220.98K-209.16K309.60K1.48M
EBITDA-7.88M-1.43M-2.11M-1.01M-341.17K
Net Income-7.95M-3.77M-6.18M-4.25M-3.03M
Balance Sheet
Total Assets5.76M7.78M1.30M1.39M2.61M
Cash, Cash Equivalents and Short-Term Investments3.39M2.14M264.87K115.40K191.70K
Total Debt155.89K172.67K22.42M18.80M19.14M
Total Liabilities1.87M2.99M25.45M19.55M20.68M
Stockholders Equity4.04M4.87M-23.58M-17.58M-17.50M
Cash Flow
Free Cash Flow-5.83M-4.66M-1.07M-684.50K-238.28K
Operating Cash Flow-5.65M-4.54M-1.01M-649.11K-167.30K
Investing Cash Flow-1.89M-115.89K-60.13K-35.39K-70.98K
Financing Cash Flow7.05M6.47M1.22M611.23K277.36K

60 Degrees Pharmaceuticals, Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.39
Price Trends
50DMA
2.31
Negative
100DMA
2.27
Negative
200DMA
3.59
Negative
Market Momentum
MACD
-0.26
Positive
RSI
27.92
Positive
STOCH
2.90
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SXTP, the sentiment is Negative. The current price of 1.39 is below the 20-day moving average (MA) of 2.13, below the 50-day MA of 2.31, and below the 200-day MA of 3.59, indicating a bearish trend. The MACD of -0.26 indicates Positive momentum. The RSI at 27.92 is Positive, neither overbought nor oversold. The STOCH value of 2.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SXTP.

60 Degrees Pharmaceuticals, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.37B-0.04-63.81%2.59%16.40%<0.01%
43
Neutral
$4.65M-181.43%109.29%-206.99%
32
Underperform
$7.12M-217.01%45.99%
15
Underperform
$4.45M-206.26%75.68%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SXTP
60 Degrees Pharmaceuticals, Inc.
1.33
-9.73
-87.97%
ADIL
Adial Pharmaceuticals
0.47
-0.84
-64.12%
DRMA
Dermata Therapeutics
0.70
-0.60
-46.15%

60 Degrees Pharmaceuticals, Inc. Corporate Events

Private Placements and FinancingRegulatory Filings and Compliance
60 Degrees Pharmaceuticals Secures $5M in Recent Offering
Positive
Jul 18, 2025

On July 15, 2025, 60 Degrees Pharmaceuticals, Inc. announced a Securities Purchase Agreement with institutional investors for a follow-on offering, which included shares of common stock and various warrants. The offering, which closed on July 16, 2025, generated approximately $5 million in gross proceeds, intended for general corporate purposes and working capital. The offering was made under the company’s registration statement declared effective by the SEC. This move is expected to impact the company’s financial operations and market positioning by providing additional capital for its ongoing projects.

The most recent analyst rating on (SXTP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 19, 2025